Longevity technology is moving from the fringes into the mainstream.
By Ling Xin, Reporter for Caijing
Editor: Wang Xiao
David Sinclair, a professor of genetics at Harvard University who has studied aging for 30 years, shared in March 2026 that the first human subject in the first clinical trial for age-reversal gene therapy has begun receiving injections.
At the end of January, Life Biosciences, a biotechnology company co-founded by Sinclair, officially received approval from the U.S. Food and Drug Administration (FDA) to launch this human clinical trial. The drug is codenamed ER-100. In early March, the status of the clinical trial center officially shifted from "planned" to "recruiting."
Entering human clinical trials is a milestone in the field of anti-aging research. It marks the first time in human history that "cellular reprogramming" technology has been applied to the human body.
What is ER-100?
In several interviews around February, David Sinclair provided a detailed breakdown of this research.
The human trials currently underway target two diseases that cause blindness. The specific operational procedure of the ER-100 trial involves using adeno-associated virus (AAV) as a vector to inject three genes—Oct4, Sox2, and Klf4 (collectively known as OSK)—directly into the patient's eye, allowing these genes to enter damaged retinal ganglion cells.
The trial also features a "switch" mechanism: the imported genes are activated only when the patient takes a low dose of the antibiotic doxycycline; once the medication is stopped, gene expression shuts down. This is considered the essence of the trial's design.
The OSK trio of genes is derived from the research of Japanese scientist Shinya Yamanaka. Yamanaka originally used four genes to revert adult cells back into stem cells.
The discovery by Shinya Yamanaka, winner of the 2012 Nobel Prize in Physiology or Medicine, showed that by introducing four specific transcription factors—now called "Yamanaka factors"—into adult cells, they can be reprogrammed to a pluripotent state similar to embryonic stem cells.
These four factors are Oct4, Sox2, Klf4, and c-Myc. However, because c-Myc is closely linked to tumor formation, early experiments showed that mice receiving all four factors suffered high mortality rates and developed tumors.
Sinclair's team took a different approach: they do not want to revert cells completely to a stem cell state, as that would be too dangerous. Instead, they want the cells to become "younger" while remaining what they are.
Consequently, Sinclair's team removed c-Myc, the factor with the highest carcinogenic risk, selecting only the first three factors and adding the "switch" mechanism. This "partial reprogramming" strategy aims to restore the cell's youthful state while preventing it from "forgetting" its identity and turning into a primitive stem cell with cancerous potential.
Sinclair stated that in monkey experiments simulating Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), ER-100 injections significantly restored the electrical signal response (pERG) of retinal ganglion cells, proving that reprogramming is effective and safe in eyes that are highly similar in structure to humans.
In 2020, Sinclair's team published research in the journal Nature demonstrating that this technology could reverse vision loss in mice with glaucoma and even regenerate damaged optic nerves.
Why choose eye diseases as the breakthrough point?
Explaining the choice to target eye diseases first, Jerry McLaughlin, CEO of Life Biosciences, told Fortune magazine that the company is employing a "staged strategy."
Another reason is that the U.S. FDA does not consider "aging" itself to be a disease. This means that any therapy targeting "anti-aging" cannot be approved through conventional clinical trial paths.
An article in MIT Technology Review noted that Life Biosciences and similar companies must position their therapies as treatments for specific age-related diseases, such as vision loss, liver fibrosis, or neurodegenerative diseases, rather than targeting the aging process itself.
Life Biosciences chose two ocular diseases. According to a statement released on January 28, 2026, the FDA approved Phase 1 human clinical trials for its new drug to treat Primary Open-Angle Glaucoma and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION).
NAION, often called a "stroke of the eye," is the most common acute optic neuropathy in people over 50 and currently has no approved treatments. Glaucoma is the second leading cause of blindness globally; according to CDC data, it is particularly prevalent in adults aged 64 to 84.
The trial will first evaluate safety in approximately 12 patients while observing whether the therapy can restore vision to some extent.
According to the trial plan, patients will take doxycycline for eight weeks while using steroids to suppress potential inflammatory reactions. Two different doses will first be tested on up to six glaucoma patients, and then one selected dose will be used for up to six NAION patients.
Commenting on the human trial in a podcast, Sinclair noted that even if only partial vision is restored, it proves more than just an ophthalmological breakthrough—it proves that in a living human body, the information of youth can be recovered. The eyes are just the beginning. Next will be the liver, the brain, the skin, and eventually the entire body.
Sinclair is adopting a pragmatic, incremental strategy, but this also means that if "whole-body rejuvenation" is indeed feasible, there is still a long road ahead before clinical application.
Aging: Just a failure to "read" genetic information?
"Once we figure out the cause of aging, we will find it is incredibly obvious; it's not complex," said Tesla founder Elon Musk at the Davos Forum in January 2026, stating that aging is a "solvable problem."
Sinclair responded to Musk on X (formerly Twitter): "Aging has a relatively simple explanation, and it is clearly reversible. Clinical trials will begin soon." Musk followed up by asking, "ER-100?" to which Sinclair replied in the affirmative.
Sinclair has long advocated for the "Information Theory of Aging." He believes that ER-100 is not just a drug, but the first human validation of this theory. The core logic is that cells do not lose the genetic information of their youth; rather, the epigenetic information—the chemical tags that determine which genes are activated or silenced and when—gradually becomes lost and chaotic.
He used an analogy: if DNA is digital information on a CD, aging is like scratches on the surface of the disc. The information is still there, but it becomes difficult to read. ER-100 acts as a "polishing agent," restoring the cell's ability to read the instructions for youth.
"Reprogramming is like the AI of the biological world; it's the hot spot everyone is investing in," commented Karl Pfleger, a prominent Silicon Valley angel investor, during an interview on longevity biotech. He views reprogramming technology as the AI of biology because of its strong versatility and platform attributes—resetting the cellular clock using specific factors (like the Yamanaka factors) can alter the aging process of an organism on a large scale, much like AI processes big data.
However, Karl Pfleger also pointed out that this is currently only a proof of concept and is far from practical application: "In an optimistic scenario, it can solve some blindness issues for some people and drive research into other indications. But it doesn't mean your doctor will soon be able to prescribe a pill that makes you young again."
Risks and controversies surrounding this technology persist. Although results in mice and non-human primates were stunning—such as successfully restoring sight in blind mice—ER-100's human clinical trials still face massive challenges.
Daniel Ives, CEO of the UK startup Shift Bioscience, told MIT Technology Review that the three-factor combination used by Life Biosciences is "not the optimal rejuvenation version," as these factors could activate hundreds of downstream genes, which in some cases might lead cells to revert entirely to primitive stem cells.
Furthermore, long-term safety is questionable: would long-term activation of these genes in the human body trigger an immune response? Additionally, where is the optimal balance between the inducing dose of doxycycline and the reprogramming effect?
According to Life Biosciences' plan, preliminary results may emerge in late 2026 or early 2027. If successful, this trial will prove the feasibility of epigenetic reprogramming in humans, providing a foundation for future research; if it fails or presents safety issues, it will force the field to re-examine technical paths and theoretical hypotheses.
Regardless, this trial by Life Biosciences will provide crucial data for the entire anti-aging field and is well worth monitoring.
Editor: Zhang Shengting
Cover image source: Visual China